Bolt Biotherapeutics   Report issue

For profit Phase 2
Founded: Redwood City CA United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04278144
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Bolt Biotherapeutics | Bolt Biotherapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

bdc-1001 (2 trials)

bdc-3042 (1 trial)

pembrolizumab (keytruda) (2 trials)

pertuzumab (perjeta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4